These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28074476)

  • 1. Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
    Blumenthal GM; Goldberg KB; Pazdur R
    Clin Pharmacol Ther; 2017 May; 101(5):572-574. PubMed ID: 28074476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
    Kern KA
    J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 6. Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
    Yao JC; Meric-Bernstam F; Lee JJ; Eckhardt SG
    Clin Cancer Res; 2013 Aug; 19(16):4305-8. PubMed ID: 23833307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The seamless approach to drug development in oncology.
    Pazdur R
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
    [No Abstract]   [Full Text] [Related]  

  • 8. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
    [No Abstract]   [Full Text] [Related]  

  • 9. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
    Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response Rate as an Approval End Point in Oncology: Back to the Future.
    Blumenthal GM; Pazdur R
    JAMA Oncol; 2016 Jun; 2(6):780-1. PubMed ID: 26913938
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
    Yamashita K; Kaneko M; Narukawa M
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
    Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
    Oncologist; 2019 Nov; 24(11):1469-1478. PubMed ID: 31320502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
    Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
    JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A note on breast cancer trials with pCR-based accelerated approval.
    Xia Y; Cui L; Yang B
    J Biopharm Stat; 2014; 24(5):1102-14. PubMed ID: 24926729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
    Bast RC; Thigpen JT; Arbuck SG; Basen-Engquist K; Burke LB; Freedman R; Horning SJ; Ozols R; Rustin GJ; Spriggs D; Wenzel LB; Pazdur R
    Gynecol Oncol; 2007 Nov; 107(2):173-6. PubMed ID: 17950384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.